Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2010

01.02.2010 | Retinal Disorders

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

verfasst von: Thomas Ach, Alexandra E. Hoeh, Karen B. Schaal, Alexander F. Scheuerle, Stefan Dithmar

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate prognostic factors of response to intravitreal bevacizumab therapy of macular edema (ME) due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).

Methods

Patients with ME due to CRVO (32 patients) or BRVO (38 patients) received intravitreal bevacizumab (2.5 mg/0.1 ml) at baseline, and every 6 to 8 weeks if OCT showed persistent or recurrent ME. Visual acuity (EDTRS), ophthalmic examination and OCT were performed at baseline and at all follow-up visits. Six to 8 weeks after first injection, baseline factors (visual acuity, central retinal thickness, age and gender) were analyzed retrospectively between patients with resolved ME (group 1) and persisting ME (group 2). At last visit, baseline factors of patients with resolved ME since first injection (group A), with recurrent ME since baseline (group B) and with persistent ME since baseline (group C) were compared.

Results

In CRVO patients, central retinal thickness (CRT) and patients’ age are prognostic predictors in bevacizumab therapy. Age of CRVO patients differed significantly between groups 1 and 2 after first injection, while CRT only showed a strong trend to thinner CRT. At last visit, age and CRT differed statistically significantly between groups A, B and C. In BRVO patients, none of the investigated factors revealed any prognostic value. In CRVO and BRVO patients, final CRT is correlated with the CRT after first injection.

Conclusion

CRT and age of patients have prognostic value in bevacizumab therapy of ME due to CRVO. CRVO patients who benefit from therapy are significantly younger and have a lower CRT at baseline than patients with persisting ME. In BRVO patients, no predictive factors for effectiveness of bevacizumab therapy could be observed.
Literatur
1.
Zurück zum Zitat Central Vein Occlusion Study Group (1993) Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group. Online J Curr Clin Trials Doc No 95 Central Vein Occlusion Study Group (1993) Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group. Online J Curr Clin Trials Doc No 95
2.
Zurück zum Zitat Berker N, Batman C (2008) Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86:245–252CrossRefPubMed Berker N, Batman C (2008) Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86:245–252CrossRefPubMed
3.
Zurück zum Zitat Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland. Ophthalmologe 104:290–294CrossRefPubMed Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland. Ophthalmologe 104:290–294CrossRefPubMed
4.
Zurück zum Zitat Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751–758PubMed Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751–758PubMed
5.
Zurück zum Zitat Klein ML, Finkelstein D (1989) Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 107:1297–1302PubMed Klein ML, Finkelstein D (1989) Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 107:1297–1302PubMed
6.
Zurück zum Zitat Badala F (2008) The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 19:234–238CrossRefPubMed Badala F (2008) The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 19:234–238CrossRefPubMed
7.
Zurück zum Zitat Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149CrossRefPubMed Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149CrossRefPubMed
8.
Zurück zum Zitat Hoh AE, Schaal KB, Scheuerle A, Schutt F, Dithmar S (2008) OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion. Ophthalmologe 105:1121–1126CrossRefPubMed Hoh AE, Schaal KB, Scheuerle A, Schutt F, Dithmar S (2008) OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion. Ophthalmologe 105:1121–1126CrossRefPubMed
9.
Zurück zum Zitat Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Volker M, Holz FG, Bartz-Schmidt KU (2006) [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. Ophthalmologe 103:471–475CrossRefPubMed Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Volker M, Holz FG, Bartz-Schmidt KU (2006) [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. Ophthalmologe 103:471–475CrossRefPubMed
10.
Zurück zum Zitat Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012CrossRefPubMed Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012CrossRefPubMed
11.
Zurück zum Zitat Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425CrossRefPubMed Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425CrossRefPubMed
12.
Zurück zum Zitat Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S (2007) Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 104:285–289CrossRefPubMed Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S (2007) Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 104:285–289CrossRefPubMed
13.
Zurück zum Zitat Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284CrossRefPubMed Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284CrossRefPubMed
14.
Zurück zum Zitat The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491 The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491
15.
Zurück zum Zitat Chen JC, Klein ML, Watzke RC, Handelman IL, Robertson JE (1995) Natural course of perfused central retinal vein occlusion. Can J Ophthalmol 30:21–24PubMed Chen JC, Klein ML, Watzke RC, Handelman IL, Robertson JE (1995) Natural course of perfused central retinal vein occlusion. Can J Ophthalmol 30:21–24PubMed
16.
Zurück zum Zitat Zhang H, Xia Y (2002) Analysis of visual prognosis and correlative factors in retinal vein occlusion. Zhonghua Yan Ke Za Zhi 38:98–102PubMed Zhang H, Xia Y (2002) Analysis of visual prognosis and correlative factors in retinal vein occlusion. Zhonghua Yan Ke Za Zhi 38:98–102PubMed
17.
Zurück zum Zitat Esrick E, Subramanian ML, Heier JS, Devaiah AK, Topping TM, Frederick AR, Morley MG (2005) Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 139:653–657CrossRefPubMed Esrick E, Subramanian ML, Heier JS, Devaiah AK, Topping TM, Frederick AR, Morley MG (2005) Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 139:653–657CrossRefPubMed
18.
Zurück zum Zitat Subramanian ML, Heier JS, Esrick E, Devaiah AK, Topping TM, Frederick AR, Morley MG (2006) Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging 37:462–467PubMed Subramanian ML, Heier JS, Esrick E, Devaiah AK, Topping TM, Frederick AR, Morley MG (2006) Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging 37:462–467PubMed
19.
Zurück zum Zitat Sasahara M, Mikawa A, Tajiri K, Kojima H, Saito I (2006) Visual prognosis of branch retinal vein occlusion with macular edema. Nippon Ganka Gakkai Zasshi 110:293–299PubMed Sasahara M, Mikawa A, Tajiri K, Kojima H, Saito I (2006) Visual prognosis of branch retinal vein occlusion with macular edema. Nippon Ganka Gakkai Zasshi 110:293–299PubMed
20.
Zurück zum Zitat Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM (1996) Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 103:551–560PubMed Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM (1996) Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 103:551–560PubMed
21.
Zurück zum Zitat Klein R, Moss SE, Meuer SM, Klein BE (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126:513–518CrossRefPubMed Klein R, Moss SE, Meuer SM, Klein BE (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126:513–518CrossRefPubMed
22.
Zurück zum Zitat Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140:256–261PubMed Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140:256–261PubMed
23.
Zurück zum Zitat Noma H, Funatsu H, Mimura T, Hori S (2008) Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 18:1017–1019PubMed Noma H, Funatsu H, Mimura T, Hori S (2008) Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 18:1017–1019PubMed
24.
Zurück zum Zitat Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412–416CrossRefPubMed Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412–416CrossRefPubMed
25.
Zurück zum Zitat Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA (2007) Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27:426–431CrossRefPubMed Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA (2007) Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27:426–431CrossRefPubMed
26.
Zurück zum Zitat Rath EZ, Frank RN, Shin DH, Kim C (1992) Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 99:509–514PubMed Rath EZ, Frank RN, Shin DH, Kim C (1992) Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 99:509–514PubMed
27.
Zurück zum Zitat Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247CrossRefPubMed Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247CrossRefPubMed
28.
Zurück zum Zitat Lang GE, Handel A (1992) Clinical and fluorescein angiography changes in patients with central retinal vein occlusion. A unicenter study of 125 patients. Klin Monatsbl Augenheilkd 201:302–308CrossRefPubMed Lang GE, Handel A (1992) Clinical and fluorescein angiography changes in patients with central retinal vein occlusion. A unicenter study of 125 patients. Klin Monatsbl Augenheilkd 201:302–308CrossRefPubMed
Metadaten
Titel
Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion
verfasst von
Thomas Ach
Alexandra E. Hoeh
Karen B. Schaal
Alexander F. Scheuerle
Stefan Dithmar
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 2/2010
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-009-1167-6

Weitere Artikel der Ausgabe 2/2010

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2010 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.